Sesen Bio Inc.

NASDAQ:SESN  
0.52
0.00 (+0.21%)
Products

Sesen Bio Says Participated In Type C Meeting With U.S. FDA

Published: 03/30/2022 12:21 GMT
Sesen Bio Inc. (SESN) - Sesen Bio Inc - on March 28, Co Participated in a Type C Meeting With U.S. Food and Drug Administration.
Sesen Bio - FDA Agreed to Majority of Co's Proposed Protocol for Additional Phase 3 Clinical Trial for Potential Resubmission of Bla for Vicineum.
Sesen Bio-fda Agreed to Majority of Statistical Analysis Plan Design Elements for Additional Phase 3 Trial for Potential Resubmission of Vicineum Bla.
Sesen Bio - Co Plans to Further Engage FDA in Coming Months to Align on Remaining Outstanding Items Related to Additional Phase 3 Clinical Trial.
Further Company Coverage: Sesno ((reuters.
Briefs@thomsonreuters.
Com;)).